Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?
Identifieur interne : 000450 ( Istex/Curation ); précédent : 000449; suivant : 000451Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?
Auteurs : Daniel Tarsy [États-Unis] ; Ross J. Baldessarini [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-05.
English descriptors
- KwdEn :
Abstract
Second‐generation antipsychotic drugs (APDs), including aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone dominate outpatient and inpatient clinical practice, having largely displaced the older neuroleptics. Modern APDs have relatively low risk for acute extrapyramidal syndromes characteristic of older neuroleptics, particularly acute dystonia and Parkinsonism, with variable risks of akathisia and the rare neuroleptic malignant syndrome. Anticipated reduction in risk of tardive dyskinesia (TD) is less well documented. Nearly 50 years after initial reports on TD, it is appropriate to reexamine the epidemiology of this potentially severe late adverse effect of long‐term APD treatment in light of current research and practice. We compared recent estimates of incidence and prevalence of TD identified with some modern APDs to the epidemiology of TD in the earlier neuroleptic era. Such comparisons are confounded by complex modern APD regimens, uncommon exposure limited to a single modern APD, effects of previous exposure to typical neuroleptics, and neurological assessments that are rarely prospective or systematic. Available evidence suggests that the risk of TD may be declining, but longitudinal studies of patients never treated with traditional neuroleptics and exposed to only a single modern APD are required to quantify TD risks with specific drugs. Long‐term use of APDs should continue to be based on research‐supported indications, with regular specific examination for emerging TD. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.20823
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000450
Links to Exploration step
ISTEX:34A6B749D9546BB2AF065F893AF882A8305E9086Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?</title>
<author><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Harvard Medical School, Boston, Massachusetts</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Parkinson's Disease and Movement Disorders Center, Beth Israel‐Deaconess Medical Center, Boston, Massachusetts, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center, Beth Israel‐Deaconess Medical Center, Boston, Massachusetts</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Baldessarini, Ross J" sort="Baldessarini, Ross J" uniqKey="Baldessarini R" first="Ross J." last="Baldessarini">Ross J. Baldessarini</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry, Harvard Medical School, Boston, Massachusetts</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Psychopharmacology Program, McLean Division of Massachusetts General Hospital, Boston, Massachusetts, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Psychopharmacology Program, McLean Division of Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:34A6B749D9546BB2AF065F893AF882A8305E9086</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.20823</idno>
<idno type="url">https://api.istex.fr/document/34A6B749D9546BB2AF065F893AF882A8305E9086/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000450</idno>
<idno type="wicri:Area/Istex/Curation">000450</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics?</title>
<author><name sortKey="Tarsy, Daniel" sort="Tarsy, Daniel" uniqKey="Tarsy D" first="Daniel" last="Tarsy">Daniel Tarsy</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Neurology, Harvard Medical School, Boston, Massachusetts, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology, Harvard Medical School, Boston, Massachusetts</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Parkinson's Disease and Movement Disorders Center, Beth Israel‐Deaconess Medical Center, Boston, Massachusetts, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Parkinson's Disease and Movement Disorders Center, Beth Israel‐Deaconess Medical Center, Boston, Massachusetts</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Baldessarini, Ross J" sort="Baldessarini, Ross J" uniqKey="Baldessarini R" first="Ross J." last="Baldessarini">Ross J. Baldessarini</name>
<affiliation wicri:level="1"><mods:affiliation>Department of Psychiatry, Harvard Medical School, Boston, Massachusetts, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Psychiatry, Harvard Medical School, Boston, Massachusetts</wicri:regionArea>
</affiliation>
<affiliation wicri:level="1"><mods:affiliation>Psychopharmacology Program, McLean Division of Massachusetts General Hospital, Boston, Massachusetts, USA</mods:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Psychopharmacology Program, McLean Division of Massachusetts General Hospital, Boston, Massachusetts</wicri:regionArea>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-05">2006-05</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">5</biblScope>
<biblScope unit="page" from="589">589</biblScope>
<biblScope unit="page" to="598">598</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">34A6B749D9546BB2AF065F893AF882A8305E9086</idno>
<idno type="DOI">10.1002/mds.20823</idno>
<idno type="ArticleID">MDS20823</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>atypical antipsychotic drugs</term>
<term>atypical neuroleptics</term>
<term>extrapyramidal syndromes</term>
<term>movement disorders</term>
<term>tardive dyskinesia</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Second‐generation antipsychotic drugs (APDs), including aripiprazole, clozapine, olanzapine, risperidone, quetiapine, and ziprasidone dominate outpatient and inpatient clinical practice, having largely displaced the older neuroleptics. Modern APDs have relatively low risk for acute extrapyramidal syndromes characteristic of older neuroleptics, particularly acute dystonia and Parkinsonism, with variable risks of akathisia and the rare neuroleptic malignant syndrome. Anticipated reduction in risk of tardive dyskinesia (TD) is less well documented. Nearly 50 years after initial reports on TD, it is appropriate to reexamine the epidemiology of this potentially severe late adverse effect of long‐term APD treatment in light of current research and practice. We compared recent estimates of incidence and prevalence of TD identified with some modern APDs to the epidemiology of TD in the earlier neuroleptic era. Such comparisons are confounded by complex modern APD regimens, uncommon exposure limited to a single modern APD, effects of previous exposure to typical neuroleptics, and neurological assessments that are rarely prospective or systematic. Available evidence suggests that the risk of TD may be declining, but longitudinal studies of patients never treated with traditional neuroleptics and exposed to only a single modern APD are required to quantify TD risks with specific drugs. Long‐term use of APDs should continue to be based on research‐supported indications, with regular specific examination for emerging TD. © 2006 Movement Disorder Society</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000450 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd -nk 000450 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Istex |étape= Curation |type= RBID |clé= ISTEX:34A6B749D9546BB2AF065F893AF882A8305E9086 |texte= Epidemiology of tardive dyskinesia: Is risk declining with modern antipsychotics? }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |